Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market (Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline, Lipoglycopeptide, Folate Antagonist; Route of Administration - Oral and Parenteral; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2030

Description

The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is estimated to attract notable expansion opportunities in the upcoming years. This growth can be attributed to many factors including increasing occurrence of the antibiotic resistant strains development among population of all age groups.

Staphylococcus aureus refers to bacteria generally seen on the skin or nose of healthy individuals. Methicillin-resistant staphylococcus aureus (MRSA) can be defined as a staphylococcus aureus type, which shows resistance to beta-lactam antibiotic named methicillin.

Some of the prominent players in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include The Medicines Company, Basilea Pharmaceutica Ltd., Allergan, Merck & Co., Inc., Pfizer, Inc., and Theravance Biopharma. Presence of several prominent companies makes the competitive landscape of the market highly intense, which encourages enterprises to use organic as well as inorganic strategies in order to stay ahead in the competition.

Leading organizations in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market are investing heavily in the clinical trials and R&D projects, which are concentrated on the formulation of exclusive drug molecules. Moreover, many players are focusing on the launch of generic drugs against the presently available products that have lost the patent exclusivity.

The COVID-19 pandemic has shown impact major industries including the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. Companies have developed several policies and strategies in order to address this issue and ensure consistent revenue generation.

Several companies from the North America region, specifically the U.S., are increasing investments toward the R&D projects, which are focused on the development of screening tools for MRSA infection. This factor has helped in making North America as leading market region in the methicillin-resistant staphylococcus aureus (MRSA) drugs market. Moreover, Asia Pacific is expected to emerge as fastest growing region for the market in the years to come.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market: Snapshot

Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact. Global MRSA drugs market accounted for a revenue of US$ 2,967.0 Mn in 2016, and is estimated to reach the value of US$ 3,908.2 Mn by the end of 2025, reflecting a CAGR of 3.2% during the forecast period.

According to CDC, two in every 100 people carry MRSA. Prolonged stay of patients in long-term health care facilities is a major factor giving rise to a serious issue of surplus MRSA infections. According to the Healthcare Cost & Utilization Project (HCUP), a family of health care databases in the U.S., the rate of deaths of hospitalized patients caused by MRSA infections is higher than non-hospitalized patients (4.7% vs. 2.1% respectively). Improved screening of antibiotic resistant strains of bacteria by using technologically advanced diagnostic tools, and upsurge in the consumption of antibiotics across the globe are the major factors expected to fuel the growth of global MRSA drugs market during the forecast period. Key companies are entering the distribution agreements with the emerging regional players to improve the accessibility of their anti-MRSA agents. Basilea Pharmaceutica, one of the leading MRSA drugs manufacturer, entered into a license agreement for its anti-MRSA antibiotic Zevtera (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (China). Such key strategies being adopted by the manufacturers is expected to propel the growth of MRSA drugs market during the forecast period. There is significant unmet need for the MRSA infection, which create huge opportunities for existing players and new entrants in the market. Also adopting the strategies such as establishing commercial partnerships for co-development and commercialization of anti-MRSA agents provide scope for opportunities in the global MRSA drugs market. However, lack of systematic surveillance for MRSA infection in developing countries is likely to hamper the growth of MRSA drugs market during 2017-2025.

The global MRSA drugs market is segmented on the basis of drug class, route of administration, and distribution channel. On the basis of drug class, the global MRSA drugs market is classified as lipopeptide, oxazolidinone, cephalosporin, tetracycline, lipoglycopeptide, folate antagonists, and others. Lipopeptide drug class held the maximum market share in 2016 in terms of revenue, owing to the established market for lipopeptides such as Daptomycin owing to efficient distribution by manufacturers and distributors across the globe. Tetracycline and Lipoglycopeptide are likely to register moderate CAGR by 2025. However, others drug class segment, which is comprised of fluoroquinolones, streptogramins, etc., is anticipated to witness significant CAGR during the forecast period, which is attributable to the rising prevalence of MRSA infection in community settings of the developing countries. Based on the route of administration, the global MRSA market is segmented into oral and parenteral. Parenteral segment accounted for highest revenue in 2016, and is expected to continue to lead the market during 2017-2025. The estimated dominance of the segment is attributed to its preference as a first line of therapy in the MRSA treatment. In terms of distribution channel, the global MRSA drugs market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Rising number of multispecialty hospitals worldwide, and improved supply of the generic MRSA drugs in the hospital pharmacies across the globe are the major factors for the dominance of hospital pharmacy segment in terms of revenue in 2016. However, online pharmacy is expected to grow at relatively significant CAGR during 2017-2025, due to availability of antibiotics on the online platform with attractive offers and discounts.

Geographically, global MRSA drugs market is divided into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for maximum revenue in 2016, owing to the strategic presence of key antibiotic manufacturing companies in the U.S. North America is estimated to remain dominant throughout the forecast period, which is attributable to the increasing investment by key players in the R&D of novel drug molecules against MRSA infection. However, rising awareness about the antibiotic resistant bacterial infections in the emerging economies of Asian countries, and rising incidence of hospital-acquired MRSA infection in India & China are the major factors for the estimated growth of Asia Pacific with relatively significant CAGR by 2025.

The prominent players operating in the global MRSA Drugs Market are Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc. Investing in the R&D and clinical trials of unique drug molecules, and introducing the generic drugs against the existing products which have lost the patent exclusivity are the major strategies being adopted by key manufacturers to stay ahead in the rising competition.

The Global MRSA drugs Market has been segmented as given below:

Drug Class

  • Lipopeptide
  • Oxazolidinone
  • Tetracycline
  • Cephalosporin
  • Lipoglycopeptide
  • Folate Antagonist
  • Others

Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market

4. Market Overview
     4.1. Drug Class Overview
     4.2. Global MRSA Drugs Market Outlook

5. Market Dynamics
     5.1. Drivers
     5.2. Restraints
     5.3. Opportunities

6. Epidemiological Assessment of Methicillin-resistant Staphylococcus Aureus (MRSA)

7. MRSA Drugs: Pipeline Analysis

8. MRSA Drugs Market: Competitive Landscape of Key Players

9. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Drug Class 
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Market Value Forecast By Drug Class, 2015–2025
            9.3.1. Lipopeptide
            9.3.2. Oxazolidinone
            9.3.3. Cephalosporin
            9.3.4. Tetracycline
            9.3.5. Lipoglycopeptide
            9.3.6. Folate Antagonist
            9.3.7. Others
     9.4. Market Attractiveness By Drug Class 
     9.5 Key Trends

10. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Route of Administration 
     10.1. Introduction & Definition
     10.2. Key Findings / Developments
     10.3. Market Value Forecast By Route of Administration, 2015–2025
            10.3.1. Oral
            10.3.2. Parenteral
     10.4. Market Attractiveness By Route of Administration 
     10.5. Key Trends

11. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Distribution Channel 
     11.1. Introduction & Definition
     11.2. Key Findings / Developments
     11.3. Market Value Forecast By Distribution Channel, 2015–2025
            11.3.1. Hospital Pharmacy
            11.3.2. Retail Pharmacy
            11.3.3. Online Pharmacy
     11.4. Market Attractiveness By Distribution Channel 
     11.5 Key Trends

12. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Region
     12.1. Key Findings
     12.2. Market Value Forecast By Region
            12.2.1. North America 
            12.2.2. Europe 
            12.2.3. Asia Pacific 
            12.2.4. Latin America 
            12.2.5. Middle East & Africa 
     12.3. Market Attractiveness By Country/Region

13. North America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Market Value Forecast By Drug Class, 2015–2025
            13.2.1. Lipopeptide
            13.2.2. Oxazolidinone
            13.2.3. Cephalosporin
            13.2.4. Tetracycline
            13.2.5. Lipoglycopeptide
            13.2.9. Folate Antagonist
            13.2.7. Others
     13.3. Market Value Forecast By Route of Administration, 2015–2025
            13.3.1. Oral
            13.3.2. Parenteral
     13.4. Market Value Forecast By Distribution Channel, 2015–2025
            13.4.1. Hospital Pharmacy
            13.4.2. Retail Pharmacy
            13.4.3. Online Pharmacy
     13.5. Market Value Forecast By Country, 2015–2025
            13.5.1. U.S.
            13.5.2. Canada
     13.6. Market Attractiveness Analysis 
            13.6.1. By Drug Class 
            13.6.2. By Route of Administration 
            13.6.3. By Distribution Channel 
            13.6.4. By Country

14. Europe Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     14.1.Introduction
            14.1.1. Key Findings
     14.2.Market Value Forecast By Drug Class, 2015–2025
            14.2.1. Lipopeptide
            14.2.2. Oxazolidinone
            14.2.3. Cephalosporin
            14.2.4. Tetracycline
            14.2.5. Lipoglycopeptide
            14.2.6. Folate Antagonist
            14.2.7. Others
     14.3.Market Value Forecast By Route of Administration, 2015–2025
            14.3.1. Oral
            14.3.2. Parenteral
     14.4.Market Value Forecast By Distribution Channel, 2015–2025
            14.4.1. Hospital Pharmacy
            14.4.2. Retail Pharmacy
            14.4.3. Online Pharmacy
     14.5.Market Value Forecast By Country, 2015–2025
            14.5.1. Germany
            14.5.2. U.K.
            14.5.3. France
            14.5.4. Spain
            14.5.5. Italy
            14.5.6. Russia
            14.5.7. Rest of Europe
     14.6.Market Attractiveness Analysis 
            14.6.1. By Drug Class 
            14.6.2. By Route of Administration 
            14.6.3. By Distribution Channel 
            14.6.4. By Country

15. Asia Pacific Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     15.1.Introduction
            15.1.1. Key Findings
     15.2.Market Value Forecast By Drug Class, 2015–2025
            15.2.1. Lipopeptide
            15.2.2. Oxazolidinone
            15.2.3. Cephalosporin
            15.2.4. Tetracycline
            15.2.5. Lipoglycopeptide
            15.2.6. Folate Antagonist
            15.2.7. Others
     15.3.Market Value Forecast By Route of Administration, 2015–2025
            15.3.1. Oral
            15.3.2. Parenteral
     15.4.Market Value Forecast By Distribution Channel, 2015–2025
            15.4.1. Hospital Pharmacy
            15.4.2. Retail Pharmacy
            15.4.3. Online Pharmacy
     15.5.Market Value Forecast By Country, 2015–2025
            15.5.1. China
            15.5.2. Japan
            15.5.3. India
            15.5.4. Australia & New Zealand
            15.5.5. Rest of Asia Pacific
     15.6.Market Attractiveness Analysis 
            15.6.1. By Drug Class 
            15.6.2. By Route of Administration 
            15.6.3. By Distribution Channel 
            15.6.4. By Country

16. Latin America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     16.1.Introduction
            16.1.1. Key Findings
     16.2.Market Value Forecast By Drug Class, 2015–2025
            16.2.1. Lipopeptide
            16.2.2. Oxazolidinone
            16.2.3. Cephalosporin
            16.2.4. Tetracycline
            16.2.5. Lipoglycopeptide
            16.2.6. Folate Antagonist
            16.2.7. Others
     16.3.Market Value Forecast By Route of Administration, 2015–2025
            16.3.1. Oral
            16.3.2. Parenteral
     16.4.Market Value Forecast By Distribution Channel, 2015–2025
            16.4.1. Hospital Pharmacy
            16.4.2. Retail Pharmacy
            16.4.3. Online Pharmacy
     16.5.Market Value Forecast By Country, 2015–2025
            16.5.1. Brazil
            16.5.2. Mexico
            16.5.3. Rest of Latin America
     16.6.Market Attractiveness Analysis 
            16.6.1. By Drug Class 
            16.6.2. By Route of Administration 
            16.6.3. By Distribution Channel 
            16.6.4. By Country

17. Middle East & Africa Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     17.1.Introduction
            17.1.1. Key Findings
     17.2.Market Value Forecast By Drug Class, 2015–2025
            17.2.1. Lipopeptide
            17.2.2. Oxazolidinone
            17.2.3. Cephalosporin
            17.2.4. Tetracycline
            17.2.5. Lipoglycopeptide
            17.2.6. Folate Antagonist
            17.2.7. Others
     17.3.Market Value Forecast By Route of Administration, 2015–2025
            17.3.1. Oral
            17.3.2. Parenteral
     17.4.Market Value Forecast By Distribution Channel, 2015–2025
            17.4.1. Hospital Pharmacy
            17.4.2. Retail Pharmacy
            17.4.3. Online Pharmacy
     17.5.Market Value Forecast By Country, 2015–2025
            17.5.1. GCC Countries
            17.5.2. South Africa
            17.5.3. Israel
            17.5.4. Rest of Middle East & Africa
     17.6.Market Attractiveness Analysis 
            17.6.1. By Drug Class 
            17.6.2. By Route of Administration 
            17.6.3. By Distribution Channel 
            17.6.4. By Country

18. Competition Landscape
     18.1.Market Player – Competition Matrix (By Tier and Size of companies)
     18.2.Market Share Analysis By Company (2016)
     18.3. Company Profiles
            18.5.1. Basilea Pharmaceutica Ltd.
                      18.3.1.1. Overview
                      18.3.1.2.Financials
                      18.3.1.3.Recent Developments
                      18.3.1.4.SWOT Analysis
                      18.3.1.5.Strategic Overview
            18.3.2. The Medicines Company
                      18.3.2.1. Overview
                      18.3.2.2.Financials
                      18.3.2.3.Recent Developments
                      18.3.2.4.SWOT Analysis
                      18.3.2.5.Strategic Overview
            18.3.3. Theravance Biopharma
                      18.3.3.1. Overview
                      18.3.3.2.Financials
                      18.3.3.3.Recent Developments
                      18.3.3.4.SWOT Analysis
                      18.3.3.5.Strategic Overview
            18.3.4. Allergan
                      18.3.4.1. Overview
                      18.3.4.2.Financials
                      18.3.4.3.Recent Developments
                      18.3.4.4.SWOT Analysis
                      18.3.4.5.Strategic Overview
            18.3.5. Merck & Co., Inc.
                      18.3.5.1. Overview
                      18.3.5.2.Financials
                      18.3.5.3.Recent Developments
                      18.3.5.4.SWOT Analysis
                      18.3.5.5.Strategic Overview
            18.3.6. Pfizer, Inc.
                      18.3.6.1. Overview
                      18.3.6.2.Financials
                      18.3.6.3.Recent Developments
                      18.3.6.4.SWOT Analysis
                      18.3.6.5.Strategic Overview

Choose License Type

Checkout Inquiry Sample